SMMT · Summit Therapeutics Inc. · Debt
$15.45
+0.12 (+0.81%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$11.85B
Shares
797.75M
Volume · Oct 27
5.04M
Avg daily vol (3M)
6.06M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 3,550,000 | 10-Q filed 2026-07-23 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 16,834,000 | 10-Q filed 2026-07-23 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
48 filings
48 filers
Visit website
Investor relations